Argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer.

They are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Argenx is listed on NASDAQ and Euronext Brussels.

Company: argenx
Fund: I
Status: Realized
Team member: Harrold van Barlingen
Technology: Therapeutics
Website: www.argenx.com